Clinical Development Committee

The Clinical Development Committee is newly established to help navigate evolving challenges and opportunities across the clinical development continuum driven by advancements in medical innovation and data science technologies. Its initial focus will be in the area of cell and gene therapy (CGT). The Committee will serve to 1) provide an educational platform to address considerations in the planning and execution of clinical development strategies, 2) identify opportunities to support the clinical research infrastructure within New Jersey’s life sciences ecosystem, and 3) convene critical stakeholders to share insights and lessons learned. Committee Members will plan and execute an event.

Committee Members:

Amici Clinical Research
 – David Rodin, M.Eng, CEO
Ferring Pharmaceuticals, Inc. – Patrick Heiser, Ph.D., Associate Vice President, Clinical Development
Sanofi – Terese Bandy, Ph.D.,  MS, CSSBB, CCRP, Head of Operations, Global Medical Capability Development

Amici Clinical Research – Robert Falcone, MD, Chief Medical Officer & Principal Investigator
Amicus Therapeutics – Paul Howard, Ph.D., Senior Director, Public Policy – Angelo Stracquatanio, MS, CEO & Co-Founder
Deloitte Consulting – Nick Lingler, MS, MBA, Strategy, Life Science R&D Practice
EY – Nick Davies, Ph.D., Partner, Life Sciences, R&D Strategy
IVERIC Bio, Inc. – Kristine Curtiss, Executive Director, Clinical Development
Matinas BioPharma, Inc. – Theresa Matkovits, Ph.D., Chief Development Officer
New Jersey Economic Development Authority – Kara Moore, Sector Lead, Life Sciences
PhageNova Bio, Inc
. – Jason Rifkin, JD, MS, President & CEO
Soligenix Inc. – Christopher Pullion, DO, Medical Director

BioNJ Committee Policy
Each BioNJ Committee has two Co-Committee Chairpersons, as identified and selected by BioNJ leadership and the working Committee. Each Committee Chairperson is elected for a two-year term. At BioNJ’s discretion, one Chairperson will transition off annually to allow for continuity of leadership.